- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Ultrasound plus biomarker finds early-stage ovarian cancer, saving lives
Ultrasound plus proteomic analysis of blood samples may help physicians identify early-stage ovarian cancer and save the lives of many women, according to researchers from the Mount Sinai School of Medicine and Vanderbilt University.
Ultrasound plus proteomic analysis of blood samples may help physicians identify early-stage ovarian cancer and save the lives of many women, according to researchers from the Mount Sinai School of Medicine and Vanderbilt University.
More than 21,500 women annually are diagnosed with the disease, 67% of them at an advanced stage. If ovarian cancer is detected at an early stage, survival is greater than 90%.
Contrast ultrasound may help confirm or eliminate the possibility that biomarkers can accurately detect early-stage ovarian cancer. Contrast agents may significantly improve the diagnostic ability of ultrasound to identify early microvascular changes known to be associated with earlystage ovarian cancer, said Dr. Arthur C. Fleischer, a coauthor of the study and a professor of radiology at Vanderbilt.
“Separately, proteomics and ultrasound are of limited value as early detection tools,” he said. “However, in combination, we will likely be able to shift from an era of diagnosing advanced stage ovarian cancer to that of early-stage disease, and save the lives of many women.”
MRI or Ultrasound for Evaluating Pelvic Endometriosis?: Seven Takeaways from a New Literature Review
September 13th 2024While noting the strength of MRI for complete staging of disease and ultrasound’s ability to provide local disease characterization, the authors of a new literature review suggest the two modalities offer comparable results for diagnosing pelvic endometriosis.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Controlled Contrast Delivery Method for Ultrasound Imaging of Fallopian Tubes
September 9th 2024Facilitating natural contrast delivery through an intrauterine catheter, FemChec can be utilized for ultrasound assessment of fallopian tubes and may provide diagnostic confirmation for an emerging non-surgical option for permanent birth control.
FDA Clears Emerging Cardiovascular Point-of-Care Ultrasound Platform
August 22nd 2024Combining four CAD modules for valvular pathologies with a variety of automated measurements, the AI-enabled AISAP Cardio ultrasound system reportedly facilitates up to a 90 percent accuracy rate in detecting common cardiac conditions.
Predicting DCIS Upgrade to Invasive Breast Cancer: Can Contrast-Enhanced Ultrasound Have an Impact?
August 21st 2024Adding two key findings from contrast-enhanced ultrasound to a predictive model of mammography, conventional ultrasound and clinicopathological findings led to a 86.1 percent AUROC for predicting the upgrading of ductal carcinoma in situ to invasive breast cancer, according to new research.
